{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:48:02Z","timestamp":1778672882190,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bioorg.2020.103803","type":"journal-article","created":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T11:01:07Z","timestamp":1585652467000},"page":"103803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Discovery of novel dual PPAR\u03b1\/\u03b4 agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"99","author":[{"given":"Zheng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuekun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongrong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2020.103803_b0005","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2020.103803_b0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2020.103803_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.metabol.2016.10.003","article-title":"Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status","volume":"66","author":"Huh","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.bioorg.2020.103803_b0020","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11901-018-0425-7","article-title":"Pathogenesis of NASH: the impact of multiple pathways","volume":"17","author":"Noureddin","year":"2018","journal-title":"Curr. Hepatol. Rep."},{"key":"10.1016\/j.bioorg.2020.103803_b0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.bioorg.2020.103803_b0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2020.103803_b0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-015-0149-2","article-title":"Promoter methylation status and expression of PPAR-gamma gene are associated with prognosis of acute-on-chronic hepatitis B liver failure","volume":"7","author":"Zhao","year":"2015","journal-title":"Clin. Epigenet"},{"key":"10.1016\/j.bioorg.2020.103803_b0040","doi-asserted-by":"crossref","unstructured":"F. Hong, S. Pan, Y. Guo, P. Xu, Y. Zhai, PPARs as nuclear receptors for nutrient and energy metabolism, Molecules (Basel, Switzerland), 24 (2019).","DOI":"10.3390\/molecules24142545"},{"key":"10.1016\/j.bioorg.2020.103803_b0045","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bioorg.2020.103803_b0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2020.103803_b0055","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.bioorg.2020.103803_b0060","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2337\/diabetes.52.7.1770","article-title":"Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis","volume":"52","author":"Kim","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.bioorg.2020.103803_b0065","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2020.103803_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030913","article-title":"PPAR beta\/delta: a key therapeutic target in metabolic disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2020.103803_b0075","doi-asserted-by":"crossref","first-page":"15924","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2020.103803_b0080","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/01.ATV.0000252790.70572.0c","article-title":"Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist","volume":"27","author":"Sprecher","year":"2007","journal-title":"Arterioscl. Throm. Vas."},{"key":"10.1016\/j.bioorg.2020.103803_b0085","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1093\/nar\/gkv331","article-title":"The transcriptional PPARbeta\/delta network in human macrophages defines a unique agonist-induced activation state","volume":"43","author":"Adhikary","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2020.103803_b0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR gamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2020.103803_b0095","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice","volume":"233","author":"Derosa","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bioorg.2020.103803_b0100","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103803_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082189","article-title":"The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development","volume":"19","author":"Hong","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2020.103803_b0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2018.09.071","article-title":"Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARgamma and PPARdelta","volume":"159","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103803_b0115","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2018.12.069","article-title":"Discovery of first-in-class thiazole-based dual FFA1\/PPARdelta agonists as potential anti-diabetic agents","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103803_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103254","article-title":"Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)\/PPARdelta agonists as potential anti-diabetic agents","volume":"92","author":"Li","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2020.103803_b0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2012.03.001","article-title":"Thiazolidinediones and PPARgamma agonists: time for a reassessment","volume":"23","author":"Cariou","year":"2012","journal-title":"Trends Endocrin. Met."},{"key":"10.1016\/j.bioorg.2020.103803_b0130","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2020.103803_b0135","doi-asserted-by":"crossref","first-page":"16912","DOI":"10.18632\/oncotarget.14818","article-title":"Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl) -2-methylphenoxy)-2-methylpropanoic acid (MHY2013)","volume":"8","author":"An","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2020.103803_b0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.tet.2014.12.043","article-title":"Significant facilitation of metal-free aerobic oxidative cyclization of imines with water in synthesis of benzimidazoles","volume":"71","author":"Lee","year":"2015","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2020.103803_b0145","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1016\/j.bmc.2018.09.006","article-title":"Discovery of DS-6930, a potent selective PPARgamma modulator. Part I: Lead identification","volume":"26","author":"Shinozuka","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2020.103803_b0150","first-page":"1650145","article-title":"Synthesis design antihyperglycemic studies, and docking simulations of benzimidazole-thiazolidinedione hybrids","author":"Gutierrez-Hernandez","year":"2019","journal-title":"J. Chem."},{"key":"10.1016\/j.bioorg.2020.103803_b0155","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.biopha.2018.09.074","article-title":"Design, synthesis, in vitro, in vivo and in silico pharmacological characterization of antidiabetic N-Boc-l-tyrosine-based compounds","volume":"108","author":"Herrera-Rueda","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2020.103803_b0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820302807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206820302807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:00:19Z","timestamp":1758614419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206820302807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":32,"alternative-id":["S0045206820302807"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103803","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel dual PPAR\u03b1\/\u03b4 agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2020.103803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103803"}}